Advertisement

Synta Pharmaceuticals’ (Nasdaq: SNTA) stock rose more than 10 percent Tuesday, and has jumped more than 32 percent since a rash of insider buys June 29. The Lexington, Mass-based biotechnology company has no approved drugs but has six mid-to-late stage clinical trials ongoing for potential cancer therapies.

Advertisement
Advertisement